Novo Nordisk reported data from the SUSTAIN 4 trial in which semaglutide significantly improved glycemic control vs. insulin glargine U100 in adults with type 2 diabetes. Semaglutide is an investigational glucagon-like peptide-1 (GLP-1) analog.
SUSTAIN 4 (n=1,089) was a Phase 3, randomized, open-label, multicenter, multinational, 30-week trial evaluating the safety and efficacy of once-weekly semaglutide vs. once-daily insulin glargine (U100/mL), both added to metformin with or without sulfonylurea.
Data from SUSTAIN 4 showed that study patients achieved statistically significant and superior improvements in HbA1c reductions of 1.2% and 1.6% when treated with 0.5mg and 1mg semaglutide, respectively vs. a 0.8% reduction with insulin glargine U100 (P<0.0001 for both). A greater percent of adults treated with semaglutide 0.5mg and 1mg met HbA1c targets vs. adults treated with insulin glargine: HbA1c <7% (57.5% and 73.3% vs. 38.1%) and HbA1c ≤6.5% (37.3% and 54.2% vs. 17.5%)
Also, adults treated with semaglutide achieved statistically significant and superior reductions in mean body weight of 3.5kg and 5.2kg vs. an increase of 1.2kg seen with the insulin glargine-treated patients (P<0.0001 for both).
The rate of serious adverse events were similar across the treatment groups (6.1% and 4.7% vs. 5.0%).
For more information call (800) 727-6500 or visit NovoNordisk-US.com.